GenSci Submits Another Blockbuster Product for Market Approval

Recently, GenSci announced that the marketing application of its Leuprorelin Injection Emulsion ( Camcevi ) has been accepted by the National Medical Products Administration ( NMPA ), and it is intended for Androgen Deprivation Therapy ( ADT ) of advanced prostate cancer. Leuprorelin Injection Emulsion is a gonadotropin-releasing hormone ( GnRH ) agonist. Administered subcutaneously, it forms a solid implant that gradually releases Leuprolide over six months with just one shot. The product can significantly enhance patient compliance through its extended dosing interval. This product is developed through the collaboration of Accord BioPharma and GenSci, and we holds the rights in the Chinese market. It has already received approval in the United States, Canada, EU, and Taiwan region of China for prostate cancer treatment. The current application for market approval will significantly enhance the convenience of using L euprorelin Injection Emulsion for patients with advanced prostate cancer. Previous: Episil® Launched in China: A Breakthrough Solution for Oral Mucositis Next: Clinical Trial Commencement of GenSci120 Injection Approved Recommended News 2026-09-03 GenSci Showcases Innovation at CPHI Korea 2026 2026-08-13 GenSci's Ophthalmology Pipeline: IND Approval Secured for Three Indications 2026-07-31 GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPA

The release as fetched from its publisher. genscigroup.com ↗